SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors.
Ontology highlight
ABSTRACT: Metastasis is responsible for over 90% of cancer-associated mortality. In epithelial carcinomas, a key process in metastatic progression is the epigenetic reprogramming of an epithelial-to-mesenchymal transition-like (EMT) change towards invasive cellular phenotypes. In non-epithelial cancers, different mechanisms must underlie metastatic change, but relatively little is known about the factors involved. Here, we identify the chromatin regulatory Sirtuin factor SIRT7 as a key regulator of metastatic phenotypes in both epithelial and mesenchymal cancer cells. In epithelial prostate carcinomas, high SIRT7 levels are associated with aggressive cancer phenotypes, metastatic disease, and poor patient prognosis, and depletion of SIRT7 can reprogram these cells to a less aggressive phenotype. Int
SUBMITTER: Malik S
PROVIDER: S-EPMC4413894 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA